Archive for January, 2020

RECENTLY Ive been searching for a word that describes our present system of government.Liberal democracyisnt quite right (though it has features of both) because the phrase omits too many of its other features: notably, the rise and dominance of cranks, the casual overriding of well-established professional rules, and the imposition of formal and informal censorship on matters of controversy.

All three hang together, and all are dealt with below, but the key one seems to me to be the rise and dominance of cranks. Several people have suggested that the wordidiocracyis the one for which Ive been looking. Its also the title of a clever comedy of a few years back which some commentators predictably argue forecast the presidency of Donald Trump. Its producers have recently coined the witty advert: The film that started as a comedy . . . but became a documentary. Fair play to them. Its a funny movie, now on video. Watch it.

But its not about Trump who, though an infuriating mix of cleverness, boldness, impulsiveness, touchiness and at times mean-spiritedness, is not an idiot, still less a crank. Theyre not the same thing, anyway. An idiot is simply a stupid person. A crank may actually be quite clever, but hes in possession of One Big Idea (or maybe two) that drives him to promote it interminably and with no sense of proportion or practicality.

Cranks have been around in politics a long time, probably always Swift lampoons them as projectors inGullivers Travels but there seem to be more of them around since the rise of ideological politics in the French Revolution and, still more significantly, with the later rise of socialism. Ideological politics are the attempt to use government to implement some ambitious project of human betterment that will avert a vast catastrophe and bring about a new ideal society without greed, inequality, division and other human vices. Both the end of the world and utopia usually figure in ideology, and its sometimes hard to tell them apart.

Crankery figures too. The nineteenth century socialist theoretician Saint-Simon believed that under socialism the oceans would turn into lemonade. That didnt happen because it was fanciful nonsense and, besides, there werent any socialist governments around to give it a try. Stalin was around in Russia by the 1930s, however, and as part of the campaign to improve grain production, he supported applying the cranky anti-scientific theories of the geneticist Trofim Lysenko to agriculture (largely because they fitted in with Marxist ideology). Grain production and Soviet agriculture suffered, but Lysenkos theories remained Soviet orthodoxy until after Stalins death. Scientists who criticised them were dismissed in large numbers and some very distinguished geneticists were imprisoned and executed.

Theres an almost logical progression here. A government claims intellectual authority in some non-political field, genetics, say, or music. Some of its pronouncements run counter to established scientific truths, but they are backed by strong pressuresfrom loss of employment to execution, and the usual professional rules and legal safeguards designed to prevent the spread of quackeries are ignored from a prudent cowardice. And when the crankish policy begins to fail, censorship is imposed and its critics are dismissed, silenced, or worse.

Crankocracy = the rise of bogus experts + the junking of professional standards and legal protections x the repression of objectors.

We might think that with Saint-Simon and Lysenko in our history we would be alert in future to such dangers. Not so.

Marxist socialism is itself one vast exercise in crankery applied to politics, philosophy and economics, and it seems to have a family affection for lesser fallacies. But only thirty years since the collapse of Soviet communism revealed the economic wastelands and the mass graves of its political victims across the USSR, there is now a growing revival of support for socialism/communism/Marxism on the Left and among young people in the Western world.

And any large movement of perverse decadence, which this surely is, will be unlikely to leave other aspects of life alone. When the rules and protections and protections that sustain civilization in one area of life and thought begin to collapse, they knock down others elsewhere just as falling dominoes spread instability across an entire table. As Auden writes inThe Fall of Rome:

Fantastic grow the evening gowns;Agents of the Fisc pursueAbsconding tax defaulters throughThe sewers of provincial towns.

One might argue that in modernity, as in modernism and dominoes, everything is ultimately disconnected from everything else. Let me suggest two areas where crankery has already won significant victories. The first is genderand transgender theory. This holds that someones identity is not determined by his/her biological sex but by his/her gender identity, which may be malleable and is anyway a matter of individual conviction. As one slogan has it: If your boy says shes a girl, then shes a girl.

That seems false to me, but even if it were true, its effects should be limited at least by its own founding theory. Our social interactions with others, whatever their theoretical identities, should always be shaped by courtesy and goodwill, including treating them as they wish within reason. But we would surely not base a transwomans medical treatment on the assumption that her gender identity is a better guide than his biological sex to what they need.

Yet hospitals, schools, colleges and woke corporations do exactly that when they make available tampons to transwomen. Athletic bodies do likewise when they decree that transwomen with male bodies are eligible to play in womens sports, with the predictable result that many able women players who might win in a fair contest are defeated. If this goes uncorrected, it will simply end in the abolition of womens sports.

Admitting transwomen into womens-only safe spaces will similarly end a civilised protection for women in a world that certainly doesnt seem to be becoming less dangerous for them. Above all, as John Whitehall has documented inQuadrant,needless human tragedies and massive lawsuits are hurtling towards us when young people persuaded to undergo transitioning surgery and drug treatments that are life-changing and unalterable at an age when they cannot possibly understand the consequences believe in adulthood they have made a terrible mistake.

In all these cases the major institutions of society have capitulated to aggressive pressure groups pushing a theory that is highly dubious, unsupported by the great majority of clinical researches, regarded by many gays and feminists as a threat to their identities, and above all damaging to its supposed beneficiaries. Not enough attention has been devoted to examining the science behind the activism. A research project on gender-transitioning by the US National Institutes of Health (NIH) did not include the control group required by the rules. And as Madeleine Kearns ofNational Reviewhas detailed,when sceptics seek to raise these questions in public meetings, they are shouted down and threatened. Crankery or should it be quackery? is followed by ignoring the rules and enforced by repression.

Its a similar story in the academys history wars, reliant as they are on student rebellions (which in reality are highly conformist) and enforced by riots and iconoclasm. These, too, are a consequence of abolishing the border between truth and falsehood in postmodern scholarship. Of course, truth is sometimes hard to discover and to distinguish from persuasively false interpretations. The answer to that is more work in the archives. For postmodern historical interpretation was refuted in the 1920s by Georges Clemenceau, who led France in the Great War. A young historian kindly explained to him that future historians would re-examine the war from different perspectives and reach different conclusions different from his own. Yes, replied Clemenceau, future historians will say many things I might dispute. But one thing they will not say. They will not say that Belgium invaded Germany.

He may have been too optimistic. Relieved of the obligations of truth and accuracy, students all too often replace research with the pre-cooked conclusions of Marxist Critical Theory, as illustrated by theNew York Times1619 Project,which starts from the conclusion that slavery is the true essence of American history. As historian Richard Brookhiser said when asked about this recently: Two weeks before those first slaves landed, the colony adopted a democratic constitution. No one owns slaves in America today. But were still voting. How often will such rebuttals be heard in colleges in which the administrators as well as the students are striving to decolonise the curriculum, and when in effect both co-operate to close down debates and shut out speakers who might enlighten them. Once again, academic (and media) crankery is followed by, first, throwing overboard the rules of scholarship and, next, by the banishment of heretics.

It might reasonably be objected that not all of these are examples of rule by cranks. In part, thats a fair criticism. The cranks are in the streets; the corridors of power contain the cowards who yield to them. But Im not sure thats much of a comfort. Im getting the queasy feeling that in about five years anyone who has criticised Greta Thunbergs absurd views on the demise of Planet Earth by next Thursday will be up before the magistrates. It seems agreed by all well-meaning people that its a coarse and brutal insensitivity to express any scepticism aboutArmageddon predicted by a child.

All of which is a little odd, not least because the feisty Ms Thunberg is not a child. Shes a young woman of some 17 years, able to vote in progressive jurisdictions, and a rather typical self-righteous adolescent too. Now, it used to be a breach of feminist etiquette to refer to young women as if they were just starting high school. Yet we have not had any feminist complaints that Gretas honorary girlhood is an offensive slight even in these much woker days.

But could you have a better illustration of the coming crankocracy than the assembled leaders of the world nodding solemnly and applauding timidly as a 17-year-old adolescent condemns them angrily for not halting the medieval plague about to descend on them unless they replace their business suits with sackcloth and ashes?

They know their place.

This article first appeared in Quadrant Online on January 19, 2020, and is republished by kind permission.

- Advertisement -

Read more:
Greta and the rise of the crankocracy - The Conservative Woman

In October 2011, Amber Broman remembers sitting in the doctors office bawling, screaming and crying out.

Minutes earlier, she had learned that the baby girl she was carrying would likely never have the chance to talk or walk, ride a bike or drive a car or be walked down the aisle on her wedding day.

We had an amniocentesis and had noticed some abnormalities in the ultrasound, Broman noted. So we saw a specialist in Indianapolis and did an amnio there too. On the ultrasound, they initially saw multiple defects within her heart, and they didnt think her esophagus was attached to her stomach. And thats when they told me what it was and that it was in every cell of her body.

The condition was Trisomy 18.

It was five weeks before the Kokomo woman was to deliver, and all she remembers hearing that day were the words incompatible with life.

According to the National Institutes of Health, Trisomy 18 is a chromosomal genetic disorder that includes a combination of birth defects that impact nearly every organ in the body. People born with the disorder, also known as Edwards syndrome, have three copies of the 18th chromosome, and most babies with Trisomy 18 die within the first year of life.

She only lived two days, Broman said, referring to her daughter she named Khloe Nicole. We chose comfort care for her because we did not necessarily want to go through having her on machines and then making those decisions. We chose to just let life take its course, and we had almost 48 full hours with her.

Broman is not alone.

The CDC describes a birth defect as a structural change present at birth that can affect any or all parts of the body. They vary from mild to severe and depending on the type of defect, some infants can go on to live healthy lives.

In the United States, a baby is born with a birth defect every four-and-a-half minutes, according to the Indiana Birth Defects and Problems Registry, which equals roughly 120,000 babies per year.

In the Hoosier state, birth defects are the second leading cause of death for infants, with over 2,500 Indiana babies born each year with some type of congenital abnormality, such as a cardiovascular, chromosomal, central nervous system or musculoskeletal defect.

In 2018 alone, the Indiana State Department of Health concluded that birth defects contributed to 6.8 deaths per 1,000 births, a slight dip from 2017.

The infant mortality rate in Indiana is the lowest its been in six years, the ISDH noted, but the rate is still one of the highest in the nation.

In recent months, Gov. Eric Holcomb has taken the infant mortality plight to the public stage, making it one of the top priorities in his administration to have the lowest infant mortality rate in the Midwest by 2024.

The state has already begun the process of achieving that goal, rolling out programs and committees with the sole focus of lowering the infant mortality rate.

One of those programs, OB Navigator, was signed into law in 2019 and works in collaboration with the ISDH, the Indiana Family and Social Services Administration and the Indiana Department of Child Services.

OB Navigator was established by Indiana House Enrolled Act 1007 and is set in place to build a network of services and support throughout Indiana to wrap our arms around moms and babies to create healthier outcomes for both, its website states.

The program works as a connection tool between women who are early in their pregnancies and individuals who can provide personal guidance for those women through the rest of those pregnancies and at least the first six months of life.

Some of that guidance includes a Moms Helpline, which is a contact center that connects pregnant women throughout Indiana to available resources and a network of prenatal and child healthcare services, the programs website cites.

In a recent press release on the subject, State Health Commissioner Kristina Box noted that OB Navigator will be available to women on Medicaid in the states highest-risk counties, and organizers of the program anticipate enacting it in 20 counties by the end of 2020.

Visit the ISDHs website at in.gov/isdh/ for more information about the program.

While doctors do say that many birth defects cant necessarily be fully prevented, there are ways to lower the risk factor.

We usually dont start doing testing until about the second trimester of pregnancy, said Dr. Andrew Barlow, OBGYN at Trinity Health Network. We start offering blood tests and ultrasounds at that time to determine birth defects. However, there are women that can undergo screening beforehand if theyre at higher risks.

Women that fall into those categories are those over 35 or women with certain medical conditions, Barlow noted.

Because fetal growth, like organ development, takes place in the first few weeks of pregnancy, Barlow said its imperative to see your doctor on a regular basis if youre planning on becoming pregnant.

Review your medical history and make sure youre healthy enough to have children too, Barlow added. And make sure that youre not taking any medication that can contribute to birth defects. Also obviously dont abuse alcohol or drugs during pregnancy either.

Its also important to take a prenatal vitamin with the right amount of folic acid [400 mg], Barlow added, which having a deficiency of can lead to brain and spine defects like spina bifida or anencephaly. Spina bifida is a birth defect in which a developing babys spinal cord fails to develop properly. Anencephaly is the absence of a major portion of the brain, skull, and scalp that occurs during the development of the embryo.

Dr. Sheila Hockman, OBGYN at Ascension Medical Group and part of a state-wide Maternal Mortality Review Committee enacted to address the issue, agreed with Barlow, while also stressing that, such as in cases like young Khloes, there is really nothing that mothers can do to prevent such a defect.

However, areas like genetic testing can still be a giant help, even if a defect is already in place, she noted.

You can do genetic testing early in the pregnancy, Hockman said. And a lot of people, when we ask them if they want to do genetic testing, theyll say no because theyre going to deliver the baby regardless.

But for us, its not a matter of keeping the pregnancy or terminating it, she continued. Its the more well-prepared we are during the pregnancy, it enables us to care possibly in a different fashion. Do they need to see a maternal fetal medical specialist or can this pregnancy be monitored like a regular uncomplicated pregnancy? Its that sort of thing.

That can sometimes mean the difference between life and death, Hockman added.

The big point I would like to get across is that there are so many of these birth defects that are preventable, especially when you look at things like maternal obesity, she said. Its a national issue, but we can do something about it, and it often just takes a healthier lifestyle.

Go here to see the original:
'Incompatible with life': Birth defects second leading cause of death for infants in Indiana - Kokomo Tribune

A Senate committee is considering a bill that would make shelter animals and those rescued from shelters the official Florida state pet. That would put adopted cats and dogs alongside the manatee as the official state marine mammal, the alligator as the state reptile, the Florida panther as the state animal and the zebra longwing as the state butterfly.

TALLAHASSEE Sometimes Florida lawmakers fight like cats and dogs. Now they are fighting for cats and dogs.

Lawmakers are entering the third week of their annual 60-day session, and the Senate is taking up an abortion bill that's been divisive. But legislators are also taking up a number of measures that probably won't get "no" votes and likely won't get lawmakers in a lather of opposition.

Among them are animal bills. A Senate committee is considering a bill that would make shelter animals and those rescued from shelters the official Florida state pet. That would put adopted cats and dogs alongside the manatee as the official state marine mammal, the alligator as the state reptile, the Florida panther as the state animal and the zebra longwing as the state butterfly.

Another bill being considered would ban the declawing of cats unless it is medically necessary. The legislative staff analysis of the bill says people usually declaw cats to protect furniture and describes why cats should be able to hang on to their claws.

"A cat's claws play an important role in various aspects of their lives. They use their claws to assist in climbing and maintaining balance, to help them fully stretch, to relieve stress through kneading, and to escape danger," the analysis reads.

Another animal bill being considered would ban the practice of pet leasing. That's essentially when a pet dealer gives a customer a loan to pay for their pet, but then repossesses the pet when the loan can't be repaid.

Another measure that's not expected to generate vocal opposition: A proposed Senate resolution would reject and condemn white supremacy and any other philosophy that espouses one group over another on the basis of race, gender, religion, color or national origin.

The resolution won't become law, but rather send a strong message that the Senate doesn't like hate.

"These philosophies are contradictory to the values, constitutional protections, and moral fiber of the United States of America and the State of Florida," the resolution reads.

A bill that would force girls under the age of 18 to get a parent's permission before getting an abortion will be considered by the full Senate on Wednesday. It's an issue that's divided Democrats who say it's an erosion of abortion rights and Republicans who say parents should be part of the decision if their daughters have a medical procedure that could affect them the rest of their lives.

Senators will be able to ask questions about the bill and Democrats will have a ton of them but won't vote on the measure until the following week. The House is also prepared to vote on a similar bill, but will likely wait to receive the Senate version.

Republican Gov. Ron DeSantis supports the measure.

The full House will take up a bill that would bar insurance companies from using home genetic testing kits in making underwriting decisions. The legislation is sponsored by Rep. Chris Sprowls, who is next in line to become House speaker. He calls the measure a matter of privacy.

The bill seeks to outlaw life, disability and long-term care insurers from denying policies or setting premiums based on markers that might be discovered through DNA home kits.

Visit link:
Florida Legislature going to the dogs (and cats) - Destin Log

Chronic disease management startup Lark Health rolled out its "Lark Prevention" tool aimed at providing behavioral health coaching to patients at risk for developing chronic conditions,according to MobiHealth News.

Business Insider Intelligence

The AI-enabled program was designed to guide users through behavioral coaching to address health issues including weight management, smoking cessation, and stress users can select an initial health area to address, and once that program is completed, they can select a second area to focus on.

The rollout of the tool is the latest move Lark has taken to expand its scope of services and the launch could expand the size of its addressable market in the digital chronic disease management space.

Lark Health has been bolstering its diabetes and hypertension management services across the last year.The startup focused its early work in the chronic disease management space, aiming to personalize diabetes prevention and management.

Lark expanded on its personalized prevention tools through a January 2019partnershipwith genetic testing giant 23andMe to incorporate genetic test data into Lark's diabetes prevention software enabling Lark's health coaches to give users more personalized health care recommendations. And Lark is seeing impressive results with its chronic disease management endeavors: Larkannouncedin September 2019 that its hypertension management program was able to significantly reduce blood pressure and decrease the risk of stroke for patients following a period of six months.

With a growing number of US citizens at-risk for chronic conditions, the new launch could help Lark widen its addressable market as it branches into new treatment areas.For example, the new tool targets weight management, and obesity is a major health issue in the US: The prevalence of obesity was nearly 40% and affected about 93.3 million US adults in 2015-2016 alone,perthe CDC.

Further, obesity is often associated with chronic conditions like type 2 diabetes, stroke, heart disease, and certain cancers which represent some of the leading causes of preventable, premature death in the US.

The launch of Lark Prevention tool makes the startup an attractive option to payers thanks, in part, to its value-based care (VBC) billing approach.Payers who areincorporatingdigital tools into their benefits packages would likely view future partnerships with Lark Health as an enticing proposition: A whopping90%of US healthcare spending is funneled into managing and treating chronic conditions, and payers are looking for ways to curtail their share of spending on members with chronic disease.

And with Lark Prevention tool targeted to at-risk patients, payers could see the tool as a means to bypass the development or progression of costly chronic conditions, thus reducing spending in the long-term. Further, payers may have little to lose in a tie-up with Lark Health, considering it employs aVBC-basedbilling approach known as "no-risk performance-based billing" in which the startup only charges payers when its members enroll in Lark and achieve improved health outcomes, making it an even more attractive potential partner.

Want to read more stories like this one? Here's how to get access:

Original post:
Lark Health launched its preventative health tool for patients at risk of chronic conditions - Business Insider Nordic

Ghaziabad: Galactorrhea, in which a whitish or greenish discharge occurs from the nipples, affects nearly 24 percent of women but has no association with breast cancer, health experts said on Thursday.

Galactorrhea is a milky nipple discharge unrelated to the normal milk production for breastfeeding. It is not a disease itself but could be a sign of an underlying problem. It usually occurs in women, even those who have never had children or after menopause.

According to the doctors at Columbia Asia Hospital in Ghaziabad, pre-menopausal women who are not breastfeeding may experience a condition where they produce breast milk.

The condition may indicate high levels of the hormone prolactin in the body, caused mainly by some malfunction in the pituitary gland that produces the hormone, the experts said.

Galactorrhea may occur when your body produces too much prolactin, (a hormone produced by the pituitary gland in the brain that stimulates the production of milk when a woman has a baby). Any woman who has had a baby, whether or not she breast-fed her baby, may later have galactorrhea, said Vinita Diwakar, Obstetrics, and Gynaecology department, Columbia Asia Hospital.

Too much estrogen in the body due to birth control pills or an underactive thyroid gland can also cause the condition. Nipple stimulation due to sexual activity or sports activities such as jogging can also increase prolactin production, Diwakar added.

According to the hospital, some of the other causes of galactorrhea may include consumption of drugs, such as oral contraceptive pills, some high blood pressure medications, sedatives, and antidepressants; disorders or non-cancerous tumours of the pituitary gland; opivid use violactinoma other medical conditions such as kidney failure, cirrhosis of the liver, and tumours of the spinal cord.

If the breast tissue is particularly sensitive to prolactin in the blood, it may cause idiopathic galactorrhea the reason for which remains unknown.

In men, galactorrhea may cause testosterone deficiency or male hypogonadism and usually occurs with breast enlargement or tenderness (gynecomastia). It may also cause erectile dysfunction and a lack of sexual desire due to testosterone deficiency, Diwakar said.

If a woman experiences a mild idiopathic galactorrhea, a tight breast support may help stop the discharge by preventing stimulation of the nipples, the doctor said.

In newborns, galactorrhea may be caused due to high maternal estrogen levels that cross the placenta and reaches the babys blood. This can enlarge the babys breast tissue, which may be associated with a milky nipple discharge, though it is temporary and resolves on its own. If the discharge is persistent, consult a doctor, Diwakar stressed.

Read more here:
Galactorrhea affects 24% women, not linked to breast cancer - The Siasat Daily

BOSTON--(BUSINESS WIRE)--Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for Research in Otolaryngology (ARO), being held January 25 to January 29, 2020 in San Jose, CA.

Akouos continues to advance our platform for inner ear disorders, and we are excited to share our progress with the scientific community, said Greg Robinson, Ph.D., chief scientific officer of Akouos. The data presented at ARO further substantiates Akouoss use of AAVAnc80 vector technology and its potential to address many forms of hearing loss.

SYMPOSIUM

Title: The Adeno-associated Viral Anc80 (AAVAnc80) Vector - Precision Genetic Medicines to Address Hearing LossPresenter: Michelle Valero, Ph.D., Director, Anatomy & Physiology, AkouosSession: Symposium 11Date and Time: Saturday, January 25, 3 p.m. (PST)

POSTER PRESENTATIONS

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Olive Baboons (Papio anubis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Cynomolgus Macaques (Macaca fascicularis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: Dual Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Non-human PrimatesDay and Time: Monday, January 27, 1 p.m. (PST)

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to improve and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit http://www.akouos.com.

About AAVAnc Technology

Ancestral AAV (AAVAnc) technology was developed in the laboratory of Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of 40,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in numerous preclinical studies.

See the original post:
Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting - Business Wire

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities. - Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancers diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancers mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing. Aberrations in alternative splicing are linked to cancers progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancers biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide. - Competitors identified in this market include, among others, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company , F. Hoffmann-La Roche Ltd., Glaxosmithkline Plc, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc.,Takeda Pharmaceutical Company Limited.

Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

CANCER THERAPIES MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Cancer Therapies: An Outlook Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market By Cancer Type USA Leads the Cancer Therapies Market Biotherapies to Drive Growth Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth Total Number of New Cancer Cases by Type: 2018 Total Number of Cancer Deaths by Type: 2018 Cancer Incidence by Region: 2018 Cancer Mortality by Region: 2018 Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018 Cancer Research Spending Continues to Witness Growth Number of FDA-Approved Cancer Drugs: 2010-2018 Select Cancer Drug Approvals in 2019 Select Cancer Drug Approvals in 2018 Cancer Drug Pipeline to Change the Pharma Landscape Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019 Global Competitor Market Shares Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019 Select Leading Cancer Drugs Worldwide by Sales: 2018

2. FOCUS ON SELECT PLAYERS AbbVie, Inc. (USA) Amgen, Inc. (USA) Astellas Pharma, Inc. (Japan) AstraZeneca Plc. (UK) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Select Late Stage Compounds in Bristol-Myers Squibb Companys Oncology Pipeline (As of 2019) Celgene Corporation (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Glaxosmithkline Plc (UK) Johnson & Johnson Services, Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) Pfizer, Inc. (USA) Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS Industry Focuses on New Approaches to Treat Cancer Recent Advancements in Cancer Drug Discovery A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team Lymphoma Therapy Developed by BeiGene Secures US FDA Approval New Linker Technology for Enhancing Stability of ADCs Personalized Medicine Gains Importance Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care North American Companion Diagnostics Market (2019) European Companion Diagnostics Market by Disease Area (2019) Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs Combination Therapy: A Double Whammy Success Patent Expiries of Branded Drugs to Trigger Generic Competition Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer Development of Novel Drug Candidates and Potential Therapies Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies Rise in Patient Assistance Programs (PAPs) Top Financial Concerns for Cancer Patients: Ranked In Order of Influence Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses Growth Drivers and Restraints Demographics & Lifestyles Raise the Risk of Cancer Percentage Breakdown of New Cases for All Cancers by Gender (2019) Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019) Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019) Unmet Needs Leave Scope for Further Research and Development Low Entry Barriers in Cancer Research Encourages Breakthrough Developments Increasing Investments by National Health Authorities NCI Funding for Cancer Research (2002, 2008, 2014 and 2020) Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth Molecular Imaging of Cancer: Critical in Improving Patient Outcomes Innovations, Improvements, and Approvals Propel Growth Select Cancer Drug Approvals (2018 & 2019) Emerging Challenges in Cancer Drug Development Drug Failures Deter Prospects of New Therapies High Prices of Targeted Therapies Act as a Speed Breaker Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016 Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation Limited Tumor Specificity and Toxicity Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance Reduced Smoking Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018 Reimbursement Coverage Remains a Major Challenge Increase in Multidrug Resistance Stringent Regulations Delay Market Approval Challenges Encountered in Clinical Trials Overview of Cancer Therapy Segments Immunotherapy: A Promising Segment Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019 Monoclonal Antibodies for Cancer Treatment Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment Vaccines: A Promising Future Area of Cancer Therapeutics Approved Therapeutic Cancer Vaccines Worldwide CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients Immune Cells for Cancer Treatment UK Researchers New Approach Holds Potential to Boost Immunotherapies Targeted Therapy: An Overview Types of Targeted Therapy Chemotherapy: An Overview Types of Chemotherapy Risks Associated with Chemotherapy Hormone Therapy Drug Classes in Hormone Therapy Cancer Types, Approved and Pipeline Drugs Prostate Cancer Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC) Prostate Cancer Phase IV Completed Clinical Trials with Results Lung Cancer Age-Standardized Lung Cancer Rates for Select Countries Age-Standardized Lung Cancer Rates in Men for Select Countries Age-Standardized Lung Cancer Rates in Women for Select Countries Select FDA-Approved Non-Small Cell Lung Cancer Drugs Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019 Select Phase III Completed Clinical Trials with Results: As of December 30, 2019 Breast Cancer Select FDA Approved Breast Cancer Drugs Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Renal Cancer Select FDA-Approved Renal Cell Carcinoma Drugs Cervical Cancer Colorectal Cancer Select FDA-Approved Colorectal Cancer Drugs Skin Cancer Skin Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Pancreatic Cancer Non-Hodgkins Lymphoma Leukemia Standard Approved Mode of Therapy for AML by Age Group Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Bladder Cancer Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE Table 1: Cancer Therapies Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Cancer Therapies Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Cancer Therapies Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Chemotherapy (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Chemotherapy (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Chemotherapy (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Targeted Therapy (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Targeted Therapy (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Targeted Therapy (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Immunotherapy (Treatment Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 11: Immunotherapy (Treatment Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 12: Immunotherapy (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 13: Hormonal Therapy (Treatment Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2to 2025 Table 14: Hormonal Therapy (Treatment Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 15: Hormonal Therapy (Treatment Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 16: Other Treatment Types (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 17: Other Treatment Types (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 18: Other Treatment Types (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 19: Blood Cancer (Cancer Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 Table 20: Blood Cancer (Cancer Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 21: Blood Cancer (Cancer Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 Table 22: Breast Cancer (Cancer Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 Table 23: Breast Cancer (Cancer Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 Table 24: Breast Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 25: Prostate Cancer (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 26: Prostate Cancer (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 27: Prostate Cancer (Cancer Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 28: Gastrointestinal Cancer (Cancer Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 29: Gastrointestinal Cancer (Cancer Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 30: Gastrointestinal Cancer (Cancer Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 31: Gynecologic Cancer (Cancer Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 32: Gynecologic Cancer (Cancer Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 33: Gynecologic Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 34: Lung Cancer (Cancer Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 Table 35: Lung Cancer (Cancer Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 36: Lung Cancer (Cancer Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 37: Other Cancer Types (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 38: Other Cancer Types (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 39: Other Cancer Types (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Overview Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market Estimated Number of New Cancer Cases and Deaths in the US (2019) Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018 Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent Personalized Medicine Gathers Momentum for Cancer Treatment in the US A Surging US Prostate Cancer Therapeutics Market Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care CMS Hikes Reimbursement Rate for CAR-T Therapy Market Analytics Table 40: United States Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 41: Cancer Therapies Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 42: United States Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 43: United States Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 44: Cancer Therapies Market in the United States by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 45: United States Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 CANADA Number of New Cancer Cases in Canada: 2019 Market Analytics Table 46: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 47: Canadian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 48: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 49: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 50: Canadian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 51: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 JAPAN Table 52: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 53: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 54: Japanese Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 55: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 56: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 57: Japanese Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 CHINA Cancer Therapies Market: Overview Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products Market Analytics Table 58: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 59: Cancer Therapies Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 Table 60: Chinese Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 61: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 62: Cancer Therapies Historic Market Analysis in China in US$ Million by Cancer Type: 2009-2017 Table 63: Chinese Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 EUROPE Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018 Market Analytics Table 64: European Cancer Therapies Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 65: Cancer Therapies Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 66: European Cancer Therapies Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 68: Cancer Therapies Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 69: European Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 70: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 71: Cancer Therapies Market in Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 72: European Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 FRANCE Table 73: Cancer Therapies Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 74: French Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 75: French Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 76: Cancer Therapies Market in France by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 77: French Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 78: French Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 GERMANY Table 79: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 80: German Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 81: German Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 82: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 83: German Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 84: German Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ITALY Table 85: Italian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 86: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 Table 87: Italian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 88: Italian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 89: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Cancer Type: 2009-2017 Table 90: Italian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED KINGDOM Table 91: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 92: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 93: United Kingdom Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 94: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 95: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 96: United Kingdom Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 SPAIN Table 97: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 98: Spanish Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 99: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 100: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 101: Spanish Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 102: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 RUSSIA Table 103: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 104: Cancer Therapies Market in Russia by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 105: Russian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 106: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 107: Cancer Therapies Market in Russia by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 108: Russian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF EUROPE Table 109: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 110: Cancer Therapies Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 111: Rest of Europe Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 112: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 113: Cancer Therapies Market in Rest of Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 114: Rest of Europe Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ASIA-PACIFIC An Insight into Asia-Pacific Market for Cancer Therapies Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019 Market Analytics Table 115: Asia-Pacific Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 116: Cancer Therapies Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 117: Asia-Pacific Cancer Therapies Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 118: Cancer Therapies Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 119: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 120: Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 121: Cancer Therapies Market in Asia-Pacific by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 122: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 123: Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 AUSTRALIA Table 124: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 125: Australian Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 126: Australian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 127: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 128: Australian Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 129: Australian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 INDIA Table 130: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 131: Indian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 132: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 133: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 134: Indian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 135: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 SOUTH KOREA Table 136: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 137: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 138: Cancer Therapies Market Share Distribution in South Korea by Treatment Type: 2009 VS 2019 VS 2025 Table 139: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 140: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 141: Cancer Therapies Market Share Distribution in South Korea by Cancer Type: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 142: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 143: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 144: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 145: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 146: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 147: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 LATIN AMERICA Table 148: Latin American Cancer Therapies Market Trends by Region/Country in US$ Million: 2018-2025 Table 149: Cancer Therapies Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 150: Latin American Cancer Therapies Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 151: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 152: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Treatment Type: 2009-2017 Table 153: Latin American Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 154: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 155: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Cancer Type: 2009-2017 Table 156: Latin American Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 ARGENTINA Table 157: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 158: Cancer Therapies Market in Argentina in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 159: Argentinean Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 160: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 161: Cancer Therapies Market in Argentina in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 162: Argentinean Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 BRAZIL Table 163: Cancer Therapies Market in Brazil by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 164: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 165: Brazilian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 166: Cancer Therapies Market in Brazil by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 167: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 168: Brazilian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 MEXICO Table 169: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 170: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 171: Mexican Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 172: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 173: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 174: Mexican Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 175: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 176: Cancer Therapies Market in Rest of Latin America by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 177: Rest of Latin America Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 178: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2to 2025 Table 179: Cancer Therapies Market in Rest of Latin America by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 180: Rest of Latin America Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 MIDDLE EAST Table 181: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 182: Cancer Therapies Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 183: The Middle East Cancer Therapies Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 184: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 185: The Middle East Cancer Therapies Historic Market by Treatment Type in US$ Million: 2009-2017 Table 186: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 187: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 188: The Middle East Cancer Therapies Historic Market by Cancer Type in US$ Million: 2009-2017 Table 189: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 IRAN Table 190: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 191: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 192: Iranian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 193: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 194: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 195: Iranian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 ISRAEL Table 196: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 197: Cancer Therapies Market in Israel in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 198: Israeli Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 199: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 200: Cancer Therapies Market in Israel in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 201: Israeli Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 202: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 203: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Treatment Type: 2009-2017 Table 204: Saudi Arabian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 205: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 206: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Cancer Type: 2009-2017 Table 207: Saudi Arabian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED ARAB EMIRATES Table 208: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 209: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 210: Cancer Therapies Market Share Distribution in United Arab Emirates by Treatment Type: 2009 VS 2019 VS 2025 Table 211: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 212: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 213: Cancer Therapies Market Share Distribution in United Arab Emirates by Cancer Type: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 214: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 215: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 216: Rest of Middle East Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 217: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 218: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 219: Rest of Middle East Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 AFRICA Table 220: African Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 221: Cancer Therapies Market in Africa by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 222: African Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 223: African Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 224: Cancer Therapies Market in Africa by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 225: African Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 75 (including Divisions/Subsidiaries - 80) Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
Global Cancer Therapies Industry - GlobeNewswire

The global "Gene Therapy Market" research report highlights the need for the up-to-date market data for the business management that will offer development and profitability of the global Gene Therapy market. The research report presents all the essential facts and figures on drifts & growths. It emphasizes on technologies & capacities, materials & markets, and unpredictable structure of the Gene Therapy market. In addition, it also highlights the dominating players in the market joined with their market share. The well-established players in the market are Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

Click Here To Access The Report: http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html#request-sample

The global Gene Therapy market report portrays best approaches to assess the global Gene Therapy market. It offers the reliable facts and extensive analysis of the global Gene Therapy market. The report presents a summary of the global Gene Therapy industry, embracing categorizations, applications, and industry chain structure. The study also represents a thorough analysis including significant insights, industry-legalized figures, and facts of the global Gene Therapy market.

Furthermore, the study also assesses the principal aspects of the market that entails revenue, demand, gross value, growth rate, cost, capability, market share, import, gross margin, expenditure, export, manufacture, supply, and so on. A number of methodological tools are used in the global Gene Therapy market analysis. It offers a complete analysis of the market statistics and the estimation of the global Gene Therapy industry players along with their market scope.

Read Detailed Index of full Research Study at:http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html

The research report highlights the assessment of its diverse segments. It also offers analysis of main topographies of the global Gene Therapy market. This profound review portrays the existing market development & drifts, key aspects impelling the market expansion, market projections, drivers, limits, and market structure. The market study also offers analysis of every area of the global Gene Therapy market along with its sub-segments. Additionally, the global Gene Therapy market report covers the major product categories and segments Ex vivo, In vivo along with their sub-segments Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others in detail.

In addition, the study emphasizes the leading market players ruling worldwide. It also provides the user with important details such as sales, contact details, product specifications & pictures, and market share. The assessment also embodies previous and expected data and statistics that make the report an extremely precious reference for advertising individuals, advisors, industry executives, sales & product executives, forecasters, and other personals hunting for crucial industry information in readily handy scripts with outstandingly displayed tables, statistics, and graphs.

There are 15 Chapters to display the Global Gene Therapy market

Chapter 1, Definition, Specifications and Classification of Gene Therapy , Applications of Gene Therapy , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Gene Therapy , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Gene Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Gene Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Gene Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Ex vivo, In vivo, Market Trend by Application Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Gene Therapy ;Chapter 12, Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Gene Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html#inquiry-for-buying

Reasons for Buying Gene Therapy market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Read more from the original source:
Global Gene Therapy Market Growth Analysis, Forecasts to 2025:2023: Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon -...

He ate, played and learned like any other kid. But David Vetter's life unfolded in a series of unusual environments: plastic, bubblelike enclosures that protected him from germs. He had severe combined immunodeficiency (SCID), and even a seemingly harmless germ could kill him.

The subject of pop culture scrutiny and medical fascination, David was called "the boy in the bubble" by the US media. SCID is rare and often fatal; it affects about 1 in 58,000 infants.

The disorder is created by genetic mutations that cause patients to produce too few of the immune cells that protect the body from infection. In healthy immune systems, T and B cells known as lymphocytes attack foreign organisms.

READ MORE:*Doctors use HIV in gene therapy to fix 'bubble boy*Eight-month old Kiwiboy facing life in a bubble*'Remarkable' progress in finding cure for HIV

People with SCID lack these critical immune defences.

David, who lived in the US state of Texas, wasn't supposed to grow up in isolation. But while doctors waited for a cure, they decided to keep him in a sterile environment.

Raising a child in plastic isolation was developmentally risky and ethically questionable. But exposing David to the outside world meant death. Doctors thought a cure was just around the corner. Meanwhile, David became a long-term research subject.

GETTY IMAGES

David Vetter, who was born with severe combined immunodeficiency (SCID), plays in the enclosed plastic environment that he was forced to live in to survive. His short life provided insights into how SCID works.

Precocious, bright and sociable, he challenged expectations at every turn. (He did have visual problems that stemmed from being raised entirely in enclosed spaces, and he exhibited symptoms of depression.)

During his long confinement, medical technology progressed. But an experimental bone marrow transplant from his sister was David's death sentence. Undetected Epstein-Barr virus in her marrow triggered lymphoma. He died of the cancer in 1984 at age 12.

Because he was brought up in a sterile environment, his death allowed researchers to confirm a long-standing hypothesis that Epstein-Barr can cause cancer.

David's short life also provided insights into how SCID works. Better bone marrow screening now means more transplants are successful. According to the Immune Deficiency Foundation, 91 per cent of infants who are diagnosed early and given transplants by age 3- months survive.

Today, David's medical records and personal papers are held by the Smithsonian Institution in Washington DC. Perhaps the most touching of the museum's artifacts are his Star Warsaction figures a painful reminder of the child at the centre of a medical drama he could not control.

View original post here:
He was called 'the boy in the bubble.' His short life gave insights into a rare illness - Stuff.co.nz

A new statistical study of the Gene Therapy Industry market was recently published by Healthcare Intelligence Market. Primary and secondary research techniques have been used to provide effective and accurate data to make informative decisions in the businesses.

At the same time, we classify different Sports Drug Testing Device based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Gene Therapy Industry industry development trends and marketing channels are analyzed.

Get Sample copy of Report@ https://www.healthcareintelligencemarkets.com/request_sample.php?id=113738

Leading Key Players Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

The global competitive landscape has been elaborated on the basis of analysis of several companies. For an effective analysis, different tools such as Porters five and SWOT analysis have been used. This research report also looks at the latest developments in technologies and business sectors like Gene Therapy Industry. Techniques that will come in handy to explore global opportunities have also been listed in the report.

Gene Therapy Industry Market segmentation, by regions:

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

Others

Special discount on this report@ https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=113738

Market Report includes major TOC points:

Gene Therapy Industry Overview

Global Economic Impact on Industry

Global Market Competition by Manufacturers

Global Production, Revenue (Value) by Region

Global Supply (Production), Consumption, Export, Import by Regions

Global Production, Revenue (Value), Price Trend by Type

Global Market Analysis by Application

Manufacturing Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Gene Therapy Industry Forecast

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Gene Therapy Industry market.

2. To provide insights about factors affecting the market growth. To analyze the Gene Therapy Industry market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Gene Therapy Industry market.

The statistical survey report also offers numerous approaches to discover global opportunities for increasing businesses rapidly. It gives a comprehensive analysis of the global Gene Therapy Industry market which calculates different verticals of businesses such as, production capacity, local consumers, global and local clients, and potential customers.

Enquiry before buying:- for more information ask our expert@ https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=113738

About US

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact us:

Marvella Lit

Phone no: +1 (888) 616-2766

Address: 90 State Office Center

90 State Street Suite 700, Albany, NY 12207

sales@healthcareintelligencemarkets.com

http://www.healthcareintelligencemarkets.com

Here is the original post:
Exclusive Growth on Gene Therapy Industry Market Forecast by 2020-2026 | Top Key Players: Bluebird Bio,Sangamo,Spark Therapeutics - Briotainment

Analysts predict that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will post earnings per share (EPS) of ($0.63) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Gene Therapies earnings, with estimates ranging from ($0.66) to ($0.57). Axovant Gene Therapies reported earnings of ($2.16) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 70.8%. The business is expected to report its next quarterly earnings report on Thursday, February 6th.

On average, analysts expect that Axovant Gene Therapies will report full year earnings of ($3.56) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($1.84). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.32) per share, with EPS estimates ranging from ($2.84) to ($1.20). Zacks Investment Researchs earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Axovant Gene Therapies.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its earnings results on Friday, November 8th. The company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($1.15) by $0.54.

Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $6.00 target price on the stock in a report on Wednesday, November 13th. ValuEngine upgraded shares of Axovant Gene Therapies from a hold rating to a buy rating in a report on Friday. Finally, Chardan Capital raised their price objective on shares of Axovant Gene Therapies from $10.00 to $15.00 and gave the stock a buy rating in a report on Monday, October 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $24.72.

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in shares of Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. Barclays PLC acquired a new stake in shares of Axovant Gene Therapies during the third quarter worth $65,000. Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Finally, BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies during the second quarter worth $1,482,000. Institutional investors and hedge funds own 14.80% of the companys stock.

AXGT opened at $4.95 on Tuesday. The firms fifty day moving average is $5.18 and its two-hundred day moving average is $6.20. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.69. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Read More: What is a capital gain?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
-$0.63 Earnings Per Share Expected for Axovant Gene Therapies Ltd (NASDAQ:AXGT) This Quarter - Riverton Roll

Former Ireland AM presenter Lorraine Keane has told how scheduled sex during her IVF battle took the romance out of her relationship.

The screen and stage star said the scientific approach to making love put a strain on her and musician hubby Peter Devlins marriage.

But the 47-year-old revealed that with the right hormone balance shes bringing sexy back.

Mum-of-two Lorraine opened up on losing clumps of hair, breaking out in adult acne and having a low libido, as the gruelling perimenopause took its grip.

She said her failed IVF attempts were directly linked to her hormone imbalance and she counts herself lucky to have her daughters.

Lorraine told Dublin Live: I kept it to myself for all of the time that we thought it might happen.

It was really difficult to come out and talk about being perimenopausal. But then it made sense to come out and talk about the whole truth.

Maybe I didnt talk about doing IVF during it because I thought, If I do have a baby maybe I wont want to say thats how we conceived.

But then I got such an amazing reaction for opening up about the menopause, it gave me the confidence to speak out and to help other women who may have an opportunity to conceive and maybe their hormones are the reason that theyre not.

Id hate for them to go through three sessions of IVF for all of those reasons, because of the mental and physical harm that it does to you, your wallet as well.

The star admitted the gruelling IVF sessions were tough on her relationship.

She said: It takes the romance out of things, before you even do the business, youre looking at calendars and scheduling in time to have sex, its not very romantic.

Im sure most men are thinking, Id love that but when youre actually in it, the pressure of, Please God make this work it takes away the spontaneity completely.

But thank God myself and Peter always had two healthy babies to go back to.

I feel for people who dont have children, we could count our blessings with the two that we have.

Opening up on her hormonal imbalance, Lorraine said: If you are going to go through menopause then you will go through perimenopause first.

Its a milder version of full-blown menopause Im told.

For example, I havent had a hot flush, or I dont have any problems with my nether regions.

I know during menopause women have terrible pain there, especially during sex, but there is so much help out there, lots of options, whether it be natural, medical, even diet can help.

The symptoms I had were I did get night sweats before I started taking MenoMin and made a visit to endocrinologist Dr Mary Ryan to check my hormone levels.

Clumps of my hair fell out in the shower, it was all hormone related, I had extensions for ages but the worst was the hormonal breakouts, adult acne.

Now I feel balanced, like the 35-year-old me I sleep better (I was waking three to five times a night), my libido has returned, Ive less joint pain, no more hair loss, no hormonal breakouts, I feel brilliant.

Lorraine was approached to front the Cleanmarine brand and despite her initial shock at being approached, shes never looked back.

With perimenopausal symptoms starting when she was 37, she wished she knew her hormones were the main reason she couldnt add to her family. She said: I didnt realise it was something I could fix, maintain and control.

Myself and Peter would have loved to have had more children but we were in one of these situations that was unexplained infertility.

I found out I went into perimenopause very young, normally its 40-plus, I was 37 or 38 going into this.

There I was spending a fortune on IVF, emotionally, physically and mentally suffering through a few phases of it.

Neither one of us were infertile, so it could have been down to hormones and the fact I was in the perimenopause.

I felt low, no energy, very slow, I was annoyed with myself because Ive so much to be grateful for and then Id feel annoyed because I wasnt singing, whistling or being chirpy about life. I discovered taking the right supplements you can have perimenopause and menopause and still be sexy, its just hormones.

Lorraine is urging the public to help support Fashion Relief in aid of Oxfam at Dublins RDS on March 27 and 28.

She said: I travelled to Bangladesh to visit the refugee camp in 2019 and raised 203,000.

To know that theyll have clean safe drinking water and to have a health clinic on site because of Fashion Relief is incredible. Not even half of that will be needed for the camp and it will keep the camp running safely for another year.

The people dont want to be there, but they cant go back home as its unsafe, so at least while there, we know theyll be safe, healthy and educated, weve teachers on site too.

That was down to everyone giving their services and talents for free, the clothes on the day people donate pre-loved designer clothing, it doesnt always have to be designer. Boutiques, wholesalers and designers all donate, its an amazing day out, everything we dont sell goes back into the Oxfam shops.

You can like our main Facebook page here.

Our Dublin Live Sports Page - which brings you all your Dublin sports news - can be found here.

The Dublin Live Twitter account is @DublinLive.

Our Instagram account can be found here.

View original post here:
Lorraine Keane reveals 'scheduled sex' during IVF battle took romance out of relationship - Dublin Live

Protein shakes have become rather essential in this modern era for people of different age groups. It does not just help you to build lean muscles and repair damaged ones, it also gives you the strength to carry out throughout the day without any loss of energy. There are several types of protein shakes in the market. Although all the brands claim to be one of the best in the market, it is not true all the time. Since it is a matter of your own health, it is important that you choose nothing but the best. Thus, TrueFit Lean Protein Shake is a good option for you.

RSP is one of the popular supplement companies that was started by a group of former student-athletes. During the initial days, the company used to concentrate only on bodybuilding products. However, with time, they shifted their focus to more general health supplements. The founders of the company state that they wish the company to become a lifestyle brand that customers can use in their everyday lives.

RSP has come up with several amino acid powder products in the past. However, TrueFit happens to be their flagship product. According to the makers, this protein shake provides users with an ideal balance of veggies, fruits, and high-quality protein, along with 9gm of carbs, dietary fiber, and healthy fats.

Every serving of these health supplements gives you 25gm of protein, 160 calories, 12gm of carbs comprising of 2gm of sugar and 8gm of fiber, and 3gm of fat. Your body will also get approximately 9% of your daily sodium and 20% of your daily cholesterol supply from each scoop. When you talk about the minerals and vitamins in the protein shake, TrueFit comprises of roughly 30% of the daily recommended dose of vitamins and minerals for an adult. This includes vitamins A, B, C, D, E, magnesium, and biotin.

The protein content in TrueFit Lean Protein Shake (see full details at mealreplacementreviewpro.com/rsp-truefit-lean-meal-replacement-reviews) comes from whey isolate and concentrate. The different flavorings of the product also come from natural flavors, cocoa, artificial sweeteners such as sucralose, and stevia. However, the product is free from artificial flavors, colors, and preservatives. Even the content of artificial sweeteners is about less than 0.1gm in each scoop.

The fiber in this product comes from 8.5gm of prebiotic soluble fiber, as well as, from sweet potato powder. It also contains 1gm of a mixture of different types of vegetables and fruits such as berries, broccoli sprouts, carrots, and tomato to name a few. The presence of 7 different digestive enzymes, such as bromelain, protease, lipase, papain, amylase, cellulose, and lactase, as well as, 1 billion probiotic bacteria ensure proper digestive health for you.

From a first timers point of view, it is a good thing that the TrueFit Lean Protein Shake comes with a good list of ingredients that focus on your gut. The pre and probiotics, digestive enzymes, and fiber ensure that your digestive system does not take a beating when you have the protein shake. These ingredients also make sure that all the essential nutrients get absorbed in your system properly, making it a great choice for those of you who suffer from digestive issues.

The high fiber content results in a low amount of net carbs in the shake, which along with low-fat content makes it a great meal replacement. In other words, it is more than a mere protein shake for you. According to the makers, one scoop of the protein shake will give you everything that your body needs in terms of nutrition. It will give you a balanced diet and also ensure that you remain full for quite some time.

However, there are some nutrients that are missing in this product. Nutrients such as choline and vitamin K are missing out in this supplement, which does not make it a nutritionally complete health drink. It even lacks zinc, iron, and potassium and contains a losing percentage of calcium. These are essential nutrients for your health and missing out on these nutrients can be dangerous in the long run.

In short, it can be said that RSP TrueFit Lean Protein Shake is rather good as a high fiber protein nutritious shake that has special attention towards your digestive system. Although it is pretty low in carbs, which is a good thing, it is also quite low in iron, fat, and potassium, which may not be that good for your health.

Continued here:
NHS Mental Health Director Claire Murdoch Warns Game Developers Of Loot Box Risks To Children - The Hear UP

Alexey Boronenkov, one of the clients of the company Kriorus, frozen brain and my 70 year old mother in the hope that it will be able to return to life with the help of scientific progress.

I took this decision because we were very close. I thought that this is the only opportunity to meet in the future, he said.

He himself is going to cryonization after death.

I Hope one day we will reach such a level that it will be possible to create an artificial body with an artificial muscle tissues and organs which may be transplanted the brain of my mother, he says.

the ContextHoliness and frozen Ilta-Sanomat18.01.2018 Stern: the Russian business aimed at Stern03.10.2018 Cryopreservation as a successful Helsingin Sanomat11.06.2017

investing in the future for tens of thousands of dollars

In the suburban tanks of the company in liquid nitrogen at minus 196 degrees stored the body or the brain 71 people and Pets. It is an expensive procedure. The preservation of the whole body will cost 36 thousand dollars, the preservation of the brain 15 thousand dollars.

This is a much higher level of average salaries of Russians. For foreigners the cost is a little higher. Customers from more than 20 countries have signed a contract with the company regarding further actions with their bodies after death.

a Firm referred to as expensive funeral Agency

the activity of the company is often criticized. Evgeny Alexandrov, the head of the Commission of Sciences to combat pseudoscience and falsification of scientific data, said the newspaper FStia that cryonics is a very commercial idea that lacks any scientific basis.

Its a fantasy, speculating on the hopes of the people about the resurrection of the dead and dreams of eternal life quoted by his newspaper.

Valeria Udalova Director of the company, her dead dog froze in 2008. She considers it likely that humanity will be able to develop the technology to revive dead people. However, she acknowledges that no guarantees for this.

According to Valerie Udalovoy, the people who pay for the procedure for preservation of bodies of relatives show how much they love their loved ones.

They need hope, she says.

What can we do for our dead relatives and loved ones? A good funeral, an album of photographs. And these people go on proving their love even stronger.

the new York times contain estimates of the solely foreign media and do not reflect the views of the editorial Board of the new York times.

Read the original post:
MTV (Finland): the Russian firm will freeze your body or brain for resurrection in the future - International Law Lawyer News

Everyone sheds about 100 hairs each day as part of the normal hair growth cycle, but excess loss is usually a distressing development.(iStock)

Hair loss is typically considered the domain of aging men, but this equal-opportunity condition which has many causes can affect virtually anyone.

Alopecia is the medical term for hair loss, and it doesnt only happen on the scalp. Some illnesses and medications can trigger balding over the entire body, though genetics account for most cases on the head, according to theCleveland Clinic.

PARTY DRUG MDMA A STEP CLOSER TO LEGALIZATION FOR PTSD THERAPY

Everyone sheds about 100 hairs each day as part of the normal hair growth cycle, but excess loss is usually a distressing development. Americans spend more than $3.5 billion each year trying to treat it, according to theAmerican Hair Loss Association.

Most peoples hair grows about a half-inch per month, and about 90 percentof your hair is actively growing at any given time, with the other 10 percentin dormant phase. After two or three months, this dormant hair falls out and its follicles begin growing new hair as other follicles begin a dormant phase.

Shedding hair is different from hair loss, when a hair falls out and doesnt grow back. People often shed hair during stressful events, such aschildbirth, a breakup or divorce or during times of grief.

It still doesnt feel good, and it takes the hair [awhile] to reach a certain length where you perceive its presence, said Doris Day, a board-certified dermatologist New York City and an attending physician at Lenox Hill Hospital, also in New York. So it feels like a hair loss, but its not a hair loss.

Aside from heredity, noticeable hair loss can be caused by wide variety of factors, including:

Harsh hairstyles or treatments: Hairstyles that consistently use rubber bands, rollers or barrettes, or pull hair into tight styles such as cornrows, can inflame and scar hair follicles. So can incorrectly used chemical products such as dyes, bleaches, straighteners or permanent wave solutions. Depending on the degree of damage, resulting hair loss can be permanent.

Hormone imbalances: In women, hormonal shifts from birth control pills,pregnancy, childbirth, menopause or hysterectomy can induce more hair follicles than normal to enter the dormant phase.

Illness or surgery: The stress from sickness or surgery may prompt the body to temporarily cease nonessential tasks such as hair production. Specific conditions can also trigger it, including thyroid disorders,syphilis, iron deficiency,lupusor severe infection. An autoimmune condition called alopecia areata, which has no cure, causes rapid body-wide hair loss.

Medications and vitamins: Cancer chemotherapy, which attacks hair follicles in its attempt to kill all fast-growing cells around the body, is a well-known reason for hair loss. Other medications side effects include hair shedding as well, such as some that treat high blood pressure andgout(a painful joint condition caused by a buildup of uric acid). Excessive levels of vitamin A also contribute.

Nutritional deficits: Heavy dieting or eating disorders such asbulimiaandanorexiacan temporarily stun hair follicles to cease growth. This can also occur from insufficient protein, vitamin or mineral intake.

Aging: A natural effect of growing older is slowed hair growth.

Women usually dont go completely bald, but lose hair on the top of the head or the temples. Men tend to lose hair on their temples, and are more likely than women to go completely bald, Day said.

Dermatologists will examine the persons scalp and take a history of medical or stressful events to see whats been going on in their life and their world, Day said.

HELICOPTER-SHARING APP BLADE PAIRS WITH NYU LANGONE TO SPEED TRANSPLANT ORGANS

The dermatologist may take a biopsy a small patch of skin that includes the hair follicle and send it to a pathologist to determine if an autoimmune disease, such as lupus, is the cause of the hair loss.

Examining the hair and follicle can also determine whether someone has a bacterial or fungal infection, Day said.

Hair loss remedies range from the mild to the extreme and the inexpensive to the costly. Much depends on how much hair is gone and how high a priority it is to mask its absence or replace it.

According to the Cleveland Clinic, treatments include:

Hair weaves or wigs: Typically expensive, wigs and hair weaves either completely cover the head or add to existing hair, restoring the appearance of a full head of hair. They are especially practical for cancer patients and those whose hair loss is temporary.

Topical creams and lotions: Over-the-counter minoxidil (also known as the brand name Rogaine) can restore some hair growth, especially in those with hereditary hair loss. It is applied directly to the scalp. Prescription-strength finasteride (Propecia) comes in pill form and is only for men. According to theAmerican Academy of Family Physicians(AFP), it may take up to six months to tell if these medications are working.

Anti-inflammatory medications: Prescription steroid-based creams or injections can calm follicles damaged or inflamed by harsh chemicals or excessive pulling.

Surgery: Men tend to be better candidates for surgical hair-replacement techniques because their hair loss is often limited to one or two areas of the scalp. Procedures include grafting, which transplants from one to 15 hairs per disc-shaped graft to other locations. Scalp reduction removes bald skin from the scalp so hair-covered scalp can be stretched to fill in the bald areas. Side effects include swelling, bruising and headaches.

Hair-growth laser treatment can also help stimulate hair follicles and improve growth, Day said. People often see results when they combine laser treatment with another intervention, she said. Treatments range in price from $30 and up for Rogaine to about $3,000 for laser treatment, she added.

According to theNational Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMSD), alternative therapies may not help hair regrow and many are not supported by medical research. However, other treatments that reportedly improve alopecia areata include Chinese herbs, acupuncture, zinc and vitamin supplements, evening primrose oil and aroma therapy.

Viviscal, a natural supplement, has also shownmore hair growthin men compared to those who took fish extract in clinical trials, Day said.

The NIAMSD recommends discussing any alternative treatments with physicians before use.

The drug Tofacitinib is approved to treat adults witharthritis, but a growing number of cases suggest that it can also treat alopecia universalis, a condition in which people lose all of the hair on their body because theirimmune systemattacks hair follicles,Live Science previously reported.

The finding occurred after doctors prescribed a 25-year-old man with alopecia universalis the drug because they had heard it had treated a similar condition in mice,according to a statement from Yale University. After three months of treatment, the man had completely regrown the hair on his scalp, and he had visible eyebrows, eyelashes, facial hair, as well as hair elsewhere on his body.

Its exciting, said Day, who did not treat this particular patient. There seems to be a real effect here.

CLICK HERE TO GET THE FOX NEWS APP

Its unclear how Tofacitinib (brand name Xeljanz) works, but researchers hope to determine its mechanism soon. This data may help them learn which biological pathways lead to hair loss.

There are now clinical trials taking place around the country to test the safety and efficacy of the drug for hair loss conditions. One such study lasting 3 months gave Tofacitinib to 66 people with alopecia areata (an immune system condition that causes hair to fall out in patches). Half of the people regrew some hair, and one-third had more than 50 percentof the hair on their scalp grow back, according to the 2016 study, published in the journalJCI Insight.

However, researchers are still working to determine the best dose needed, whether the results are lasting, and whether they can develop a topical form of the drug, Day said. She added that patients should be aware that Tofacitinib has side effects. Its already associated with an increased risk of serious infections, as well as stomach and intestinal tears, according to Pfizer, the manufacturer.

Besides investigating Tofacitinib, researchers are also looking at ways to clone hair or use stem cell therapy to treat alopecia, Day said.

This article first appeared on LiveScience.

Originally posted here:
Alopecia: What causes the hair loss condition? - Home - WSFX

Photo: Kohei Hara/Getty Images

Like everyone else, I wonder all the time: Why am I always tired? But sometime last fall, I started getting extra droopy every afternoon. Even when Id done all the right things slept eight hours, eaten a healthy lunch, exercised Id be fighting to keep my eyes open by 4 p.m. On one of those days, as I waged war against my thousand-pound eyelids, a friend started complaining to me about her new glasses, which shed been forced to buy because contact lenses irritated her eyeballs in the dry winter air. As a fellow contact-lens wearer, I realized that perhaps my 4 p.m. sleepiness problem wasnt that I was tired maybe my eyes were. When I tested my theory and used Visine drops in the afternoons, my midday nap attacks went away.

Of course, most fatigue problems arent so easily solvable. Even the simplest fix to sleep more can be hard to come by, especially when theres an underlying problem in the mix. Unfortunately, most tiredness feels about the same; Lyme disease doesnt really give you a different flavor of exhaustion than, say, an iron deficiency or garden-variety night of tossing and turning. But if you look at other symptoms accompanying your fatigue, you might find clues to where its coming from.

If your tiredness is chronic and inexplicable or just feels off you should consult a doctor, as it could be a red flag for something more serious. And either way, its a problem you should be able to solve. To understand more about the different types of fatigue, I spoke to Dr. Jaclyn Tolentino, a primary care physician at Parsley Health, as well as Dr. Richard Firshein, a general practitioner and insomnia specialist who runs the Firshein Center in Manhattan. Here are the most common culprits of exhaustion, and how to treat them.

Hormone fluctuations can turn anyone into a nap machine, as anyone whos ever had PMS knows. But chronic hormonal imbalances can make you sleepy and grumpy all month long. The good news is that doctors can test for the presence of most hormones, so they should be able to diagnose an imbalance if you have one; most are also largely treatable with medication and/or nutritional changes. One common issue is underproduction of estrogen or progesterone, which can cause tiredness, irritability, unpredictable periods, and night sweats. (If you wake up feeling like youve just run a marathon in your pajamas, this could be your issue.)

Other hormones that can disrupt your sleep if they get out of whack are melatonin and cortisol, which are produced by your pituitary glands. You can get supplements of the former from almost any drugstore, but Dr. Tolentino recommends taking no more than 3 milligrams. The amount of melatonin your body produces is tiny compared to the melatonin supplements you can buy, so most people are actually taking much more than the body needs or should have, making the imbalance worse, she says. In other words, taking melatonin supplements to help you sleep at night could actually be contributing to your overall tiredness during the day the irony, I know!

If your tiredness coincides with weight gain, dry skin, and constantly feeling cold, you could be having issues with your thyroid, which produces hormones that regulate your metabolism, among other things. Hypothyroidism is one of the most common conditions associated with fatigue, says Dr. Tolentino. Other symptoms of hypothyroidism include constipation, hair loss, and irregular menstrual cycles. If youre experiencing any of these symptoms, its best to consult a doctor as soon as possible.

Take it from someone whos frequently anemic no matter how much steak I eat: The tricky part of getting enough vitamins and minerals is that certain nutrients are essential for the absorption of others so if you arent getting enough of one, then youre probably missing out on a bunch. Common deficiencies that cause fatigue include iron, magnesium (which contributes to the bodys absorption of iron as well as other nutrients), B vitamins, and vitamin D (which your body produces when its exposed to sunlight which doesnt happen much in the winter). Your doctor can test for all of the above, but for what its worth, Ive been taking magnesium powder every night before bed for the past six months, and it has made a huge difference in how I feel every morning. Dr. Tolentino says she recommends it to many of her patients, because it binds to melatonin and supports its production in your body.

You cant sleep because youre staring at the ceiling, ticking through all the things you messed up that day and didnt get done, and now youre extra stressed because youre stressed, and if you dont get to sleep soon then youll be even more stressed tomorrow, and blah blah stress is bad and we all need to manage it better. But in addition to making you miserable and annoying, chronic stress actually causes the overproduction of cortisol (see No. 1), a hormone that disrupts sleep. Ignore the problem and it spirals, causing weight gain, more sleeplessness, and a whole host of other issues.

You know what youre supposed to do for stress: Take breaks. Exercise. Cultivate supportive relationships. Meditate. And get enough sleep. But those things take time and energy, which seem in short supply when youre dealing with a firestorm at work (or just normal life). Dr. Firshein recommends what he calls mini-meditations, which he practices himself. Its a huge luxury to be able to set aside 30 minutes or an hour to meditate, but if you take just a few moments throughout the day, it can have a similar effect, he says. In between every patient, I take ten or 20 seconds to breathe deeply, do some visual imagery, and relax my muscles before I move on. By the end of the day, it adds up to 15 or 20 minutes of meditation. He urges patients to do the same every time they check their phone, for example, or get a text from a certain person, or get up from their desk at work. If you reset your mind consistently throughout the day, then it can keep anxiety from sneaking up on you.

Its true: Certain genes have been linked to chronic fatigue issues, including a specific one known as the CLOCK gene (yep), which is linked to faulty circadian rhythms. People with wonky CLOCK genes have issues with their metabolism, body temperature, blood pressure, and liver functions, among others. Luckily, its very rare.

A more common genetic mutation that could disrupt your sleep is one that affects your bodys ability to process alcohol, says Dr. Firstein. Alcohol causes a lot of sleep problems in itself, but some people are predisposed to be even more sensitive to it.

A doctor can test for these genes, although it can be expensive to do so and insurance may not cover the lab costs. Before you go down that rabbit hole, look at your family history do any of your relatives have similar bad reactions to alcohol, or other symptoms of the CLOCK gene? While you cant change your own genetic makeup, identifying a genetic issue can help you and your doctor come up with a plan to treat the problems that stem from it.

Speaking of alcohol and sugar, caffeine, your phone, your laptop, your TV screen, your neighbors music, your roommates music, LED lighting, your newborn kid, or the fries you just ate, you are surrounded by things that cause you to sleep poorly and be tired the next day. Both Dr. Firshein and Dr. Tolentino said that lifestyle is usually the No. 1 cause of tiredness, but the good news is that you can do something about it.

Weve become a little bit lazy around sleep, says Dr. Firshein. Good sleep hygiene begins hours before you actually go to bed. It takes discipline to power down at the end of the day, turn off the TV and the computer, and cut back on external light, noise and stimulus. If youre not able to do all that (because, come on), he recommends at least wearing blue-light-blocking glasses, dimming the lights, and not eating or exercising within two to three hours of bedtime.

And finally, pony up the $20 to buy an actual alarm clock and put your phone in another room before you go to bed. Ive personally found this helpful not only for falling and staying asleep, but also for getting out of bed in the morning. Instead of snoozing my phone a million times and then lazing around scrolling through garbage, I actually get up and brush my teeth and start my day after my alarm goes off, for the most part. One other tip: I sleep with a white noise machine and earplugs. (I live next to a fire station, so.)

Does your bedmate frequently shove you in the middle of the night to get you to pipe down? Do you have allergies or get a lot of sinus infections? You might have sleep apnea, a deviated septum, or another issue that inhibits your breathing and stops you from getting the kind of deep sleep that makes you feel truly rested. There are various solutions for these problems, ranging from special breathing machines to surgery; youll want to consult a doctor if you suspect you fall into this camp.

Hopefully not! But fatigue is often the most obvious symptom of autoimmune conditions like lupus, fibromyalgia, and Hashimotos thyroiditis, says Dr. Tolentino. The same goes for chronic infections like Lyme disease. Often these conditions are accompanied by other symptoms. But just like with sleep apnea, dont waste time trying to self-diagnose and get to a doctor.

Get the Cut newsletter delivered daily

More here:
What Kind of Tired Are You? - The Cut

High school and college athletes in Kentucky would only be allowed to compete in sports that align with their biological sexand not their preferred gender identityunder a bill that a state lawmaker filed Friday.

Sen. Robby Mills, R-Henderson, introduced Senate Bill 114 and titled it the "Save Womens Sports Act."

The bill calls for students to only participate in sports and use athletic facilities that correspond with the sex listed on their birth certificates.

If astudent's birth certificate has been edited or if the student's biological sex is officially challenged, then the student would have to undergo a medical examination performed and signed by a physician, physician's assistant or advanced practice registered nurse.

The examination would establish the student's sex based solely on "internal and external reproductive anatomy," testosterone levels and an "analysis of the student's genetic makeup," according to the bill.

Mills could not immediately be reached for comment.

More: Lawsuit: Louisville Christian school,conservative writerouted 'rainbow cake girl'

SB 114 would allow students who have been "deprived of an athletic opportunity" or who have suffered "any direct or indirect harm" or privacy violations due to violations of the bill's regulations to school districts and universities within two years "after the harm occurred."

Chris Hartman, executive director of the Louisville-based Fairness Campaign, an LGBTQ advocacy organization, said the bill is "once again a solution in search of a problem" and "a plea for votes in an election year."

"This is clearly part of a politically motivated (and)expanding slate of hate that's being introduced in the state targeting all LGBTQ people but with particular emphasis on transgender students," Hartman said. "...Imagine how hard it is for trans kids already on a daily basis. This bill tells them they shouldn't be participating in athletics."

"Transgender kids want to join sports teams for all the same reasons any other student does," Hartmanadded.

The Kentucky High School Athletic Association currently has a policy that recognizes the ability of transgender student-athletes to compete in sports "free from unlawful discrimination based on sexual orientation."

But some still view the KHSAA policy as restrictive, as it requires transgender athletes to undergo sex reassignment surgeryeither before or after puberty inorder to compete in sports based on their gender identity.

If reassignment surgery occurs after puberty, then transgender student-athletes in Kentucky must demonstrate that they've taken or are taking hormone therapy "for a sufficient length of time to minimize gender-related advantages in sports competition," according to the KHSAA policy.

As The Courier Journal reported last year, Kentucky was one of nine states with such policies for transgender high school athletes.

Southern Pride:LGBTQ athletes in Kentucky face challenges as an 'invisible minority'

Hartman said "few, if any" transgender students can currently meet the KHSAA guidelines, making Mills'bill unnecessary.

"I guarantee that Sen. Mills doesn't have a single instance in Kentucky athletics that this bill would address, not a single one," Hartman said. "If he can bring a witness to the table whom this applies to...I'd be shocked."

The topic of transgender athletesin Kentucky came up during the 2019 gubernatorial race between DemocratAndy Beshear and then-Republican Gov. Matt Bevin when aconservative political action committee released an ad claiming Kentucky boys are changing their gender to participate in high school sports.

The ad from the Virginia-based Campaign for American Principlesfeatured a narrator saying that Beshear the state's attorney general at the timewho is now governor after beating Bevin in November's election "supports legislation that would destroy girls' sports."

It showed a male competitor portraying a transgender girl and passinga group of female runners tofinishfirst.

The new proposal from Mills related to high school and college athletes is not the only bill in the 2020 legislative session that deals with transgender students.

House Bill 132 would bartransgender students from usingrestrooms that alignwith their gender identities.

State Rep. David Hale, R-Wellington, is the lead sponsor of the bill, which is titled the "Kentucky Student Privacy Act"and says non-transgender students could suffer"potential embarrassment, shame and psychologicalinjury" by using the same restroom or changing room as their transgender peers.

LGBTQ advocates have called Hale's bill "dangerous" and warned it would contribute to depression and suicide rates among transgender youth.

A similar bill has been introduced inpast General Assembly sessions, including one proposal in 2015 that would have allowedstudents to sue aschool for $2,500 ifthey encountered a person of the opposite biological sex in a bathroom or locker room and staff hadallowed it or failed to prohibit it.

State Sen. C.B. Embry Jr., R-Morgantown, proposed the2015 version of the "Kentucky Student Privacy Act" in response to a 2014 controversy at Louisville's Atherton High School in which the principal allowed a transgender student who was born male but identifies as a female to use the girls' bathrooms and locker rooms.

A bipartisan group of Kentucky lawmakers are also behind a push to ban conversion therapy in the Bluegrass State.

On Politics:Can conversion therapy ban pass if top Kentucky lawmakers don't understand it?

This story may be updated.

Reach Billy Kobin at bkobin@courierjournal.com or 502-582-7030. Support strong local journalism by subscribing today: courier-journal.com/subscribe.

Read or Share this story: https://www.courier-journal.com/story/news/politics/ky-general-assembly/2020/01/25/kentucky-bill-would-require-athletes-compete-based-sex-birth-not-gender-identity/4575196002/

Go here to read the rest:
Kentucky bill would require athletes to compete based on sex at birth - Courier Journal

]]> Royal Tank Regiment upgraded Challenger 2s. Credits: Elbit Systems UK. Sign-up to the Army Technology newsletter

The upgrade, which delivers an urbanised Challenger 2 variant, was developed by the Royal Tank Regiment to meet soldiers needs and identifies and fills the capability gap between the British Armys forces and adversaries in urban combat.

Supported by Army HQ, project Streetfighter II is aimed at adding modifications to the existing Challenger II Main Battle Tank (MBT) to improve lethality, situational awareness and infantry-tank cooperation of ground forces.

The vehicle was recently trialled at the UKs urban operations facility at Copehill Down Village on Salisbury Plain, where the Streetfighter was put through its paces in an urban combat environment testing a range of upgrades from industry partners.

This year Streetfighter demo built on earlier experience of the project that began in 2018 and saw the upgrades showcased to a range of senior military figures and officials from the Defence Science Technology Laboratory (Dstl).

The Streetfighter II MBT demonstrated by the British Army featured a range of lethality upgrades including heavier, more lethal machine gun systems to provide dismounted infantry better support fire.

The most notable upgrade was one of the two urbanised Challengers being equipped with a Brimstone anti-tank guided missile system designed to neutralise the threat of heavily armoured, highly survivable land platforms at long-range.

The Brimstone, made by MBDA, is designed to destroy fast-moving vehicles alongside tanks and other lighter-armoured vehicles as well as fixed positions like bunkers and can be fired from a range of platforms.

On the situational awareness front, the Streetfighter concept greatly improves the ability of mounted and dismounted personnel to communicate and understand their environment, with communications improved to let personnel on the ground directly communicate with those inside the tank.

The upgraded Challenger features a host of cameras to provide a 360-degree view of the area outside the tank; the original Challenger 2 has a limited field of view and the upgrades mean the commander and gunner can now see everything around them.

The Streetfighter II variant also features a barrel-mounted camera to enable the tank commander and crew to see around corners before they approach them, alerting them and the following personnel in advance of any previously hidden threats.

A major situational awareness upgrade comes in the form of Elbit Systems UKs IronVision platform which uses a heads-up-display (HUD) to provide tank crews with full 360 situational awareness.

The zero-latency system allows the crew to have a full picture of their operating environment despite being under armour by feeding in a picture from outside the tank into the HUD.

Elbit Systems UK CEO Martin Fausset said: It is great to see Elbit Systems UK supporting the UK Armed Forces as they enhance their battlefield protection systems for urban environments. We relish the opportunity to protect our servicemen and women in the field and are pleased to see the IronVision system delivering in this capacity.

IronVision pulls together the feeds from the various cameras outside the MBT and then converts them into a single picture where the tank operator only needs to turn their head to see a different view of outside the vehicle, rather than cycle through cameras on a screen.

Elbits IronVision system. Credits Elbit Systems UK.

On the slightly more low-tech front, the MBT also supports infantry by physically lightening the load on personnel by carrying extra gear from medical equipment to ammunition, and the addition of a storage rack to carry an urban assault kit.

The improved Challenger 2 is also fitted with steps built into the side of the vehicle allowing personnel to mount and dismount the platform more easily. One of the tanks is also fitted with a plough to clear obstructions from the urban environment allowing personnel to continue moving forward and acting as a makeshift stretcher to transport injured personnel out of the combat environment.

It is unclear whether the upgrades made by the Royal Tank Regiment will be employed across the wider fleet of Challenger 2 vehicles. However, in the British Armys wider plans for tanks, the life-extension programme continues to be a priority, in order to continue the service life of the vehicle and maintain the ability of the UK to deploy MBTs into battle.

Current plans for the Challenger 2 life extension programme are slowly drawing to a close after first being tabled in 2013. Any decision on the future of the Challenger 3 will now likely become wrapped up in the planned UK Strategic Defence and Security Review (SDSR) which will look at the needs of the Armed Forces and help guide their future shape.

At Defence IQs International Armoured Vehicles 2020, British Army director capability, Major General Jez Bennett reaffirmed the commitment to the vehicle and outlined the scope of the current life extension programme.

Bennet said: The Challenger 2 programme aims to deliver an enhanced main battle tank, with greater lethality and survivability that will provide precision direct fire and intimate support to the infantry until well into the next decade.

Read the original here:
Streetfighter and the future of the Challenger 2 - Army Technology

In another sign that the nuclear arms race is heating up, the U.S. is ramping up production of nuclear bomb cores.

The National Nuclear Security Administration (NNSA) has announced that it plans to increase theproduction of plutonium pits to 80 per year. The grapefruit-sized pits contain the fissile material that give nuclear weapons such tremendous power.

Production will center on the Mixed-Oxide Fuel Fabrication Facility at Savannah River site in North Carolina, which would be modified to manufacture at least 50 pits per year, and Los Alamos National Laboratory in New Mexico, which would generate at least 30, by 2030.

Americas nuclear weapons cores are aging, with some pits dating back to the 1970s, leading to concerns about the reliability of the U.S. nuclear stockpile.

The U.S. lost its ability to produce pits in large numbers in 1989, when the Rocky Flats Plant near Denver, Colorado, was shut down after the Federal Bureau of Investigation and Environmental Protection Agency investigated environmental violations at the site, noted Physics Today magazine in 2018. Up to 1,200 pits per year had been manufactured there.

Since then, only 30 pits for weapons have been fabricatedall at LANL [Los Alamos National Laboratory], the sole U.S. facility with production capability. Weapons-quality pit production ceased in 2012, when LANL began modernizing its 40-year-old facilities, although several practice pits have since been fabricated. The oldest pits in the stockpilewhich now numbers 3,882, according to DOEs National Nuclear Security Administration (NNSA)date to 1978.

In its 2018 Nuclear Policy Review, the Trump administration called for 80 new plutonium pits per year. Congress has also allocated large sums, with $4.7 billion alone allocated in FY 2019 for maintenance and life extension of the nuclear stockpile. The NNSA says it is legally mandated to ensure a capacity of at least 80 pits per year.

Though the production of nuclear cores has been an issue for years, a looming U.S.-Russia arms race makes the situation even more sensitive. Russia is fielding a new generation of strategic nuclear weapons, including a hypersonic nuclear-armed glider and an air-launched ballistic missile. The Trump administration has withdrawn from the 1987 Intermediate-Range Nuclear Forces treaty with Russia, alleging Russian violations, leading to fears that a new competition will beget the return of nuclear-armed, medium-range ballistic and cruise missiles.

Anti-nuclear groups are furious. Expanded pit production will cost at least $43 billion over the next 30 years, argues the Natural Resources Defense Council and other groups. Yet the Defense Department and NNSA have never explained why expanded plutonium pit production is necessary. More than 15,000 plutonium pits are stored at NNSAs Pantex Plant near Amarillo, Texas. Independent experts have concluded that plutonium pits have reliable lifetimes of at least 100 years (the average pit age is less than 40 years). Crucially, there is no pit production scheduled to maintain the safety and reliability of the existing nuclear weapons stockpile. Instead, proposed future pit production is for speculative new-design nuclear weapons, but those designs have been canceled.

Introducing a new generation of nuclear weapons could adversely impact national security because newly produced plutonium pits cannot be full-scale tested without violating the global nuclear weapons testing moratorium.

Michael Peck is a contributing writer for the National Interest. He can be found on Twitter and Facebook.

See the article here:
The U.S. is Boosting Production of Nuclear Bomb Cores (For More Nuclear Weapons) - The National Interest Online

Key point:America's F-16 has lasted a long time and has been given many upgrades. However, the F-16 might not be as good against the very best that Beijing and Moscow can throw at it.

You May Also Like: 5 Best Submarines of All Time, 5 Best Aircraft Carriers of All Time, 5 Best Battleships of All Time and Worst Submarine of All Time.

The F-16 fighter was originally conceived as a lightweight fighter for the United States and her NATO allies. In the U.S. Air Force, the Fighting Falcon would comprise the low end of a high-low mix of super-capable F-15s and cheaper, less capable F-16s. Among NATO allies, it would be a frontline fighter to replace aging planes like the F-104 and F-15.

Inevitably, the capable little single-engine fighter was pushed towards a more diverse array of missions. Originally conceived as just carrying short-ranged AIM-9 Sidewinder missiles, it gained the ability to launch the beyond visual range AIM-7 Sparrow and AIM-120 AMRAAM. Over time it gradually evolved into a versatile air-to-ground platform with the ability to accomplish close air support, battlefield air interdiction and air defense suppression missions with a variety of precision-guided missiles, including the AGM-65 Maverick missile, AGM-88 HARM anti-radar missile and Joint Directed Attack Munition precision-guided bomb.

A confluence of eventsincluding a series of budget-draining wars in the Middle East for which the F-16 has been good enough and delays in the F-35 Joint Strike Fighter programhave conspired to keep the F-16 flying much longer than originally intended. Why the F-16 is still in service is fodder for another article, but the bottom line is that it is serving today and is seriously outmatched by a new generation of Russian and Chinese fighters.

First, lets look at one of the most recent and popular versions of the F-16, the Block 50 variant. Block 50 features a AN/APG-68 V(5) radar, F100-PW-229 afterburning turbofan engine, and the AN/ALE-47 threat adaptive countermeasure system. The Block 50 has a maximum sustained speed of Mach 1.89, a range of 360 miles on internal fuel, and a ceiling described as above 50,000 feet. It can carry up to six AIM-9 Sidewinder short-range infrared homing missiles or six AIM-120 AMRAAM beyond-visual-range missiles, or some combination of either.

Despite the F-16s longevity, obsolescence was inevitable. The F-16 will not fare well against a powerful new generation of Russian and Chinese fighters. The Moscows Su-35 Flanker and PAK-FA fighter and the Beijings J-20 stealth fighter, all previously described here, have rendered the Fighting Falcon obsolete.

Although based on an contemporary of the F-16, the original Su-27 Flanker, the Su-35 has been more thoroughly updated than the spunky American fighter. The Su-35 may not be stealthy, but it can detect and engage the F-16 before the F-16 can detect it, and this puts the American plane at a big disadvantage. In a one-on-one fight, the F-16 will probably not even be able to get the Su-35 into dogfighting range, where the smaller fighters legendary maneuverability would come into play.

The new Russian PAK-FA and Chinese J-20 fighters will have similar advantages, except their stealthy design will ultimately mean F-16s wont even detect their adversaries before they realize they are being targeted by beyond-visual-range guided missiles, launched by aircraft that only visible on radar for the brief moment their internal weapons bay doors are open.

What could be done to give the F-16 better odds? The latest variant of the Fighting Falcon, the F-16V, will have the APG-83 Scalable Agile Beam Radar (SABR) radar, the first AESA radar retrofitted into the platform. SABR has been described as fifth-generation fighter technology, and indeed promises earlier detection, tracking and identification of targets sooner than older radars. The Republic of China Air Forces F-16s will be the first to be brought up to -V standard. The U.S. Air Force is pondering a service life extension program (SLEP) for select aircraft in the F-16C fleet, and the SABR radar is an obvious candidate for inclusion.

Yet improving the F-16s detection ability is only half the problem. While stealth has its disadvantages and countermeasures are inevitable, its also true that, like radar and electronic countermeasures, stealth is now permanently part of the essential feature set of modern combat aircraft. While China and Russia tout new anti-stealth measures, they are also making certain their own new aircraft are as stealthy as possible. That both countries, struggling to catch up with the United States, are still willing spend on stealth is a ringing endorsement of its value.

While SABR will likely improve the F-16s ability to detect fifth-generation fighters such as PAK-FA and the J-20, it will still be easy for enemy aircraft to detect. The F-16s lack of stealth is not something that can be addressed with upgrades to the airframe or an electronics package. The only solution is a new aircraft.

The F-16 still has a great deal of value against smaller, less technologically advanced air forces and air defenses, as well as low- to mid-intensity conflicts such as Libya and Syria. Its also useful as a bomb truck, carrying long-range munitions such as the JASSM cruise missile behind a protective wall of F-22 and F-35 fighters. But thanks to PAK-FA and the J-20, its days as a day-one frontline fighter are over. As the F-35 enters service with the United States and with its NATO and Asian allies, the F-16 begins its long, well-earned flight into the sunset.

Also From TNI: Donald Trump: The Worst President Ever?

Also From TNI: Donald Trump: Best President Ever?

Also From TNI: Why Japan Really Lost Pearl Harbor

Also From TNI: What Happens if North Korea Nuked Washington?

Kyle Mizokami is a defense and national security writer based in San Francisco who has appeared in the Diplomat, Foreign Policy, War is Boring and the Daily Beast. In 2009 he cofounded the defense and security blog Japan Security Watch. You can follow him on Twitter: @KyleMizokami. This first appeared in September 2016.

Image: Reuters.

Link:
How Does the Air Force's F-16 Stack up Against the Best Chinese and Russian Fighters? - The National Interest Online

Blue AgaveMarkethas been provided in the latest report launched by Market.usthat primarily focuses on the World industrytrends, demand, Share, Consumption and Growth and Future Forecast 2020-2029.

The report begins with a brief introduction regarding the major factors influencing theBlue Agave Marketcurrent and future growth, challenges, and opportunities, restraints, and trends. The Blue Agave market purpose of the report is to define the market requirements by describing the market information, dynamics, business plans, and segmentation. The researchers provide a detailed study of important parameters for top players including current development, gross margin, market share, future development strategies, product collection, product, and revenue.

Get Exclusively Free Sample Of This Report in PDF @https://foodnbeveragesmarket.com/report/blue-agave-market/request-sample

[Note:Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology]

The report includes an in-depth analysis of the vendor landscape and total business profiling of leading players(Nutragreen Biotechnology, Carruba, Futureceuticals, Bio Botanica, Life Extension, Mazza Innovation) of the Blue Agave Market. This research could help players to identify profit-making opportunities available in the Blue Agave Market. The study presents details on the market share which each country estimates for, as well as the effective growth opportunities expected for each geography. The reports implementing complete analytical data on the geographical segments, which includeNorth America, Europe, and Asia-Pacific, South America, Middle East, and Africa.

On the basis of product,Blue Agave Market report presents size, revenue, product cost, market share and growth rate of each type:

LiquidPowder

On the basis of the end users/applications,Blue Agave Market report concentrates on the status and opportunity for major applications/end users:

PharmaceuticalsFood and BeveragesNutraceuticalsCosmetics and Skin CareOthers

Geographic Coverage And Analysis(Regional Production Growth by 2020, World Approaching Demandand Forecast by Countries etc.):

The Middle East and Africa (GCC Countries and Egypt)

North America (USA, Mexico, and Canada)

South America (Brazil etc.)

Europe (UK, Italy, France, Turkey, Germany, Russia, etc.)

Asia-Pacific (Philippines, Korea, Thailand, Vietnam, China, Malaysia, Japan, India, Indonesia, and Australia)

Place An Inquiry Before Investment (Use Corporate Details Only):https://foodnbeveragesmarket.com/report/blue-agave-market/#inquiry

Highlights of This Report:

1. The report offers a brief analysis of the Blue Agave Market

2. In-depth information about the emerging segments as well as regional Blue Agave Market

3. To analyze {post_title}} Market size, forecast the market

4. To classify drivers and challenges for Blue Agave Market

5. To identify Blue Agave Market based on Fleet type, application and regional distribution

6. Competitive study of Blue Agave market players in analyzing the latest trends and business strategies

7. Blue Agave Market report provided concerning price trends and production volume.

The report presents complete information to identify market segments that help to increase the quality of business decision-making based on demand, sales, and product based on application-level analysis and regional level

To Get Instant Access, Purchase Report Here:https://foodnbeveragesmarket.com/purchase-report/?reportId=133995&licenseType=single_user&action=Purchase+Report

Table of ContentsDescribing Detail Research Report :

1. Introduction

2. Research Methodology

3. Report Summary

4. Blue AgaveMarket Overview

Introduction

Drivers

Restraints

Industry Trends

Porters Five Forces Analysis

SWOT Analysis

5. Global Blue AgaveMarket Research, By Product

6. Blue Agave Market Outline, By Applications

7. Blue Agave Market Description, By Regions

8. Competitive Overview

9. Company Profiles

10. Appendix?

AboutFood Beverages Market

Food Beverages Market Research is the terminal where all industrial, commercial and profitmaking venture will get the best research reports of the market in all sectors like automotive, electronics, pharmaceuticals and healthcare, food and beverages etc. The company aims to fulfill market research requirements of both national and international clients. We provide you the important and necessary information to identify and analyze the need of market and the market size.

CONTACT US :

Mr. Benni Johnson

Market.us (Powered By Prudour Pvt. Ltd.)

Email:inquiry@market.us

Address:

420 Lexington Avenue,

Suite 300 New York City,

NY 10170, United States

Tel: +1 718 618 4351

Here is the original post:
Global Blue Agave Market analysis on current and future market trends Up to 2029 - Neptune Pine

Chemical nerve agents are some of the most horrifying tools of war today. The compounds kill by paralyzing the nervous system and have been used in devastating attacks on civilians or soldiers in war zones. And they can appear, albeit in smaller doses, in pesticides used in developing countries, endangering farm workers after prolonged exposure.

For years, researchers have been searching for antidotes or treatments that could save those afflicted by these deadly chemicals. In a paper out today in Science Translational Medicine, a team from the U.S. Army Medical Research Institute of Chemical Defense has announced a potential solution: a gene therapy that grants immunity to the effects of nerve agents like sarin.

Nerve agents are compounds that interfere with a persons nervous system. As the chemicals pass through a body after exposure to skin or through inhalation, they disable an enzyme called acetylcholinesterase thats needed for communication between neurons. The results are devastating: An affected person will involuntarily discharge tears, saliva, urine and feces, experience seizures and paralysis, and rapidly die from asphyxiation.

Scientists have found that that certain enzymes in the body called bioscavengers find and break down the toxic nerve agent molecules in the body, disabling them and preventing harm. In earlier work, the Maryland-based team found that a certain variation of a enzyme made in the liver called PON1 was particularly effective. When injected into a mouse, it granted immunity to nerve agents effects temporarily. But now the team has used a gene therapy to coax the body to make the enzyme, continually, on its own.

In the new study, the team focused on a gene that carries the instructions for the most potent version of the PON1 enzyme, called PON1-IF11. By putting the gene into a virus a common technique used to deliver a gene to a host they were able to successfully introduce PON1-IF11 into mice. After injecting the rodents, just once, with the viral vector containing the gene, the mice became immune to the common nerve agents tabun, sarin, cyclosarin and soman.

The results were encouraging. "[I felt] great satisfaction and excitement," said Venkaiah Betapudi, a molecular cell biologist and first author of the paper, in an email. "[I'm] anxious to take this work to next level and make this modern medicine available to our soldiers."

The immunity lasted for the full 5 months of the study, but in theory, it should last for the lifetime of the animal.

As long as the animal lives, the enzyme is there," says Nageswararao Chilukuri, who leads the research group. "We stopped [the study] at five months after the injection, but if we had measured 6 months, 7 months, 8 months I think it will be there. We just dont have the data to show it.

But Chilukuri emphasizes that were a long way from seeing anything close to a nerve agent vaccine for humans that uses the new technique.

Gene therapy products are only for diseases right now, he explains. We are trying to use this for healthy people. We dont know the long-term safety profile of the viral vectors. We have to be absolutely sure that when we inject a virus, that 50 years from now it will not be toxic or cause any complications.

But when it does come of age, it could have broad applications. "This modern medicine can protect sniffing dogs in the battlefield and TSA and border security operations," says Betapudi.

Luckily, many researchers studying gene therapy more broadly are asking these questions too, so answers may soon emerge regarding the safety of this type of gene therapy.

[Editor's note: This post has been updated to include comments from Venkaiah Betapudi, and to clarify the respective contributions of Nageswararao Chilukuri and Betapudi.]

Originally posted here:
New Gene Therapy In Mice Could Offer Lasting Protection Against Nerve Agents - Discover Magazine

Data further supports Akouoss use of AAVAnc80 technology delivered via intracochlear administration to potentially improve hearing

Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for Research in Otolaryngology (ARO), being held January 25 to January 29, 2020 in San Jose, CA.

"Akouos continues to advance our platform for inner ear disorders, and we are excited to share our progress with the scientific community," said Greg Robinson, Ph.D., chief scientific officer of Akouos. "The data presented at ARO further substantiates Akouoss use of AAVAnc80 vector technology and its potential to address many forms of hearing loss."

SYMPOSIUM

Title: The Adeno-associated Viral Anc80 (AAVAnc80) Vector - Precision Genetic Medicines to Address Hearing LossPresenter: Michelle Valero, Ph.D., Director, Anatomy & Physiology, AkouosSession: Symposium 11Date and Time: Saturday, January 25, 3 p.m. (PST)

POSTER PRESENTATIONS

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Olive Baboons (Papio anubis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Cynomolgus Macaques (Macaca fascicularis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: Dual Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Non-human PrimatesDay and Time: Monday, January 27, 1 p.m. (PST)

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to improve and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit http://www.akouos.com.

About AAVAnc Technology

Ancestral AAV (AAVAnc) technology was developed in the laboratory of Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of 40,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in numerous preclinical studies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005380/en/

Contacts

Katie Engleman, 1ABkatie@1abmedia.com

Read the original:
Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting - Yahoo Finance

Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.

Data to be presented at the conference showcase how Decibels drug discovery and translational platform is enabling the development of an array of therapeutic programs, including DB-020 to treat cisplatin-induced ototoxicity and a gene therapy to treat congenital deafness caused by a deficiency in the otoferlin gene. In an invited symposium, Jonathon Whitton, Au.D., Ph.D., director of clinical development, will highlight how Decibel has leveraged its industry-leading, single-cell genomics and bioinformatics capabilities as part of a broader gene therapy platform to optimize therapeutic solutions for hearing loss and balance disorders.

"Over the past year, we have made significant advances in a number of our programs. These developments demonstrate the strength of our unique approach and will continue to enable our efforts in restoration and regenerative medicine approaches to the inner ear," said John Lee, executive vice president, pharmaceutical development.

The Decibel team will have a total of eight posters and presentations during this years meeting.

Podium Presentations

SYMP 12 | Moving Gene Therapies for Hearing Loss into the ClinicDate & Time: Saturday, January 25, 3:15 p.m. PT

PD 35 | Dissecting the Differentiation Fates of Hair Cells in the Vestibular Sensory Epithelia during Mouse Inner Ear Development using Single Cell TranscriptomicsDate & Time: Sunday, January 26, 11:00 a.m. PT

Poster Presentations

PS 60 | Development of Middle-Ear-Muscle Reflex (MEMR) Biomarker in Mouse

PS 143 | Multivariate Polygenic Risk Scores Identify Individuals At-Risk for and Protected from Hearing Loss

PS 184 | Natural History and Disease Progression in Two Rodent Models of Monogenic Hearing Loss

PS 463 | DB-020 Protects Cells from Cisplatin Cytotoxicity in vitro and Hair Cells in a Guinea Pig Model of Cisplatin Induced Ototoxicity

PS 692 | Tailored AAV-based Transgene Expression in the Inner Ear with Cell Type-Specific Promoters

PS 714 | Characterization of an Acute and Cyclic Cisplatin-Induced Hearing Loss in Male Fischer-344 Rats

About Decibel Therapeutics, Inc.Decibel Therapeutics, a development-stage biotechnology company, has established the worlds first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel is advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibels lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. For more information about Decibel Therapeutics, please visit decibeltx.com or follow @DecibelTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005232/en/

Contacts

Matthew Corcoran, Ten Bridge Communicationsmcorcoran@tenbridgecommunications.com (617)-866-7350

Read more here:
Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference - Yahoo Finance

At the Bio International Convention held last year in Philadelphia, The Discovery Labs announced it was opening 1.6 million square feet of coworking space and collaborative labs for healthcare, life sciences and tech companies out of GlaxoSmithKlinesformer campus in King of Prussia.

About half a year later, nearly all its square footage has been accounted for, Audrey Greenberg, executive managing director of the Discovery Labs, told Technical.ly.

Included is a big get for the region: The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a contract development and manufacturing organization and specialty investment company, the Discovery Labs announced this week.

The Center for Breakthrough Medicines leased 680,000 square feet of Discovery Labs facility to provide pre-clinical through commercial manufacturing of cell and gene therapies, including process development, plasmid DNA, viral vectors, cell banking, cell processing and support testing capabilities.

Its goal is to to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies, Discovery Labs said.

Today brilliant scientists are advancing an unprecedented number of gene and cell therapy drug candidates. The real tragedy, however, is a scarcity of manufacturing know-how, which is complex and expensive, said Alex Karnal, partner and managing director of Deerfield Management and a board member of the Discovery Labs, in a statement. It is hoped that the Center for Breakthrough Medicines will help realize the promise of cell and gene therapies in time to treat the many patients who need them.

TheCenter for Breakthrough Medicines has initiated a substantial hiring effort, with plans to hire more than 2,000 team members within the next 30 months in positions like Ph.D. scientists, manufacturing experts, lab technicians and support staff.

Greenberg called the company an end-to-end solution for companies that are looking to manufacture their solutions and products.

There wasnt really space for that to happen, and were in a biotech epicenter, she said. Companies can grow within our space.

An early rendering of The Discovery Labs. (Courtesy image)

First leases within the 1.6 million square feet across campus will likely be taken up by 10 to 20 companies in the first quarter of 2020. Many, including the Center for Breakthrough Medicines, will move into the space in Q3 or Q4 of 2020, after renovations are complete and labs are outfitted to each companys needs.

The campus is also getting a biotech incubator, Unite IQ, which will offer space to emerging life sciences startups with resources needed to initiate business operations. Unite IQ tenants will be able to use the discovery, development, testing and manufacturing capabilities of the Center for Breakthrough Medicines and tech transfer from research lab to large-scale production.

Currently, Philadelphia is home to the only Discovery Labs campus, but the company is looking toward expanding with locations on the West Coast, in Asia and in Europe.

The region is continuously growing as a hub for life sciences, andGreenberg cited King of Prussias proximity to top cell and gene therapy talent, area hospitals and patient pools as important to the Discovery Labs. Also important, she noted, was access to the Philadelphia International Airport (and its supply-chain abilities with cold storage function for transporting cell therapies).

The work is extremely important to Greenberg personally, she said.

Theres an immediacy to this work, in this industry thats working on cures for patients who are dying every day, she said. To me, this work is doing well by doing good.

See the rest here:
A cell and gene therapy development center is taking 680K square feet at KOP's Discovery Labs - Technical.ly